Aikium is pioneering the world’s first AI-designed, trillion-molecule protein screening platform — Yotta-ML², driven by an extraordinary fusion of wet lab scientists and deep learning experts. Aikium's patented SeqR protein scaffold engages, in a sequence-specific manner, intrinsically disordered regions of target proteins that have evaded antibody-based approaches. With promising cell-based data for high-value in-house multipass membrane protein targets, Aikium has unlocked the $100 billion market in oncology and immune disorders where GPCRs and ion channels have been implicated. The Aikium team has a proven track record of building transformative technologies at 10x Genomics, Atomwise, and NVIDIA. Co-founder and CEO Dr. Eswar Iyer, a Church Lab alum and a recognized innovator with over 100 patents and three commercial products, leads the efforts to push the boundaries of AI-powered protein drug discovery.